CN110742880A - Cl419在制备治疗炎性肠病药物中的用途 - Google Patents

Cl419在制备治疗炎性肠病药物中的用途 Download PDF

Info

Publication number
CN110742880A
CN110742880A CN201911111832.XA CN201911111832A CN110742880A CN 110742880 A CN110742880 A CN 110742880A CN 201911111832 A CN201911111832 A CN 201911111832A CN 110742880 A CN110742880 A CN 110742880A
Authority
CN
China
Prior art keywords
inflammatory bowel
bowel disease
acid
application
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911111832.XA
Other languages
English (en)
Inventor
王颢
刘聪
施赟杰
赵权权
胡世杰
杜继聪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Changhai Hospital
Original Assignee
Shanghai Changhai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Changhai Hospital filed Critical Shanghai Changhai Hospital
Publication of CN110742880A publication Critical patent/CN110742880A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及生物医药领域,具体涉及CL419在制备治疗炎性肠病药物中的用途。

Description

CL419在制备治疗炎性肠病药物中的用途
技术领域
本发明涉及生物医药领域,具体涉及CL419在制备治疗炎性肠病药物中的用途。
背景技术
炎性肠病(inflammatory bowel disease,IBD)是以肠道非特异性炎症损伤为特征的慢性复发性疾病,包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn'sdisease)。通过肠镜检查,可以观察到肠粘膜充血、水肿、颗粒样改变甚至溃疡形成;在组织病理学上病变区域广泛溃疡形成伴有大量中性粒细胞浸润和肠粘膜坏死。然而,炎性肠病的发病机理目前并没有明确的定论,可能与基因易感性、外界环境刺激、自身免疫以及肠道菌群失调有关。
CL419是一种多胺TLR2激动剂,来源于Pam2CSK4,用阳离子精氨酸组取代Ser-(Lys)4。CL419形成带正电荷的脂体,使其变得复杂核酸,并将其输送到细胞醇和细胞核。CL419与核酸的复合物由TLR2和核识别酸性传感器,导致NF-kB和IRF路径显著激活。在体内,CL419与质粒DNA复合(pDNA)和注射在肿瘤内诱导适度减少。
Figure BDA0002272943800000011
发明内容
本发明要解决的技术问题是:提供一种CL419的新用途。
在本发明的第一方面,提供了CL419或其药学上可接受的盐在制备治疗炎性肠病药物中的用途。
本发明化合物药学上可接受的盐,具体的可列举上述化合物与盐酸、氢溴酸、硫酸、硝酸磷酸等无机酸的盐,与甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、甲磺酸、对甲基苯磺酸等有机酸和天门氨酸、谷氨酸等酸性氨基酸的酸形成的盐。
CL419作为一种TLR2激动剂,其已公开的用途是用于抗肿瘤,发明人意外发现,其具有治疗炎性肠病的新用途。
在本发明的第二方面,提供了一种药物组合物,其含有治疗量的CL419或其药学上可接受的盐及药学上可接受的辅料。
本发明的有益效果在于首次发现并证实了CL419对DSS(葡聚糖硫酸钠)诱导的小鼠肠炎具有良好的治疗效果。
附图说明
图1为对照组(n=9)与处理组(n=6)小鼠从口服DSS饮用水后的生存期折线图。
具体实施方式
以下结合实例说明本发明,但不限制本发明。在本领域内,技术人员对本发明所做的简单替换或改进均属于本发明所保护的技术方案内。
材料与方法:
小鼠:雄性野生型C57小鼠(6-8周)购于中国科学院(上海)。所有小鼠均饲养于第二军医大学(上海)动物实验中心无特殊病原体(SPF)实验室。处理组小鼠连续3天给予50ug/ml CL-419(购自上海源溪生物科技有限公司)腹腔注射,后给予1.5%DSS(40,000kDa;ICN Biochemicals)饮用水口服7天后转为正常饮用水。对照组小鼠与处理组小鼠同一时间给予1.5%DSS饮用水口服7天后转为正常饮用水。
生存期实验:记录对照组(n=9)与处理组(n=6)小鼠口服DSS饮用水15天后的生存期。附图1显示腹腔注射CL419的处理组小鼠生存期明显好于对照组小鼠。对照组小鼠的平均生存天数是9.2天,CL419的处理组小鼠平均生存天数是11.5天。
以上所述的仅是本发明的优选实施方式,应当指出,对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。

Claims (2)

1.CL419或其药学上可接受的盐在治疗炎性肠病中的用途。
2.一种药物组合物,其特征在于含有治疗量的CL419或其药学上可接受的盐及药学上可接受的辅料。
CN201911111832.XA 2019-10-24 2019-11-14 Cl419在制备治疗炎性肠病药物中的用途 Pending CN110742880A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911017309 2019-10-24
CN2019110173090 2019-10-24

Publications (1)

Publication Number Publication Date
CN110742880A true CN110742880A (zh) 2020-02-04

Family

ID=69283222

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911111832.XA Pending CN110742880A (zh) 2019-10-24 2019-11-14 Cl419在制备治疗炎性肠病药物中的用途

Country Status (1)

Country Link
CN (1) CN110742880A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065861A1 (en) * 2010-03-23 2013-03-14 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
EP2769738A1 (en) * 2013-02-22 2014-08-27 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US20170239347A1 (en) * 2014-01-24 2017-08-24 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065861A1 (en) * 2010-03-23 2013-03-14 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
EP2769738A1 (en) * 2013-02-22 2014-08-27 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US20170239347A1 (en) * 2014-01-24 2017-08-24 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer

Similar Documents

Publication Publication Date Title
US11065286B2 (en) High mobility group box I mutant
JP6552117B2 (ja) 敗血症の予防治療剤
CN101790380A (zh) 合成tlr激动剂的缀合物及其应用
JP2006515859A5 (zh)
CN103402545A (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
WO2019107530A1 (ja) 炎症性腸疾患の治療薬
ES2797048T3 (es) Composiciones para administración por vía oral que comprende una variante de una proteína de pliegue OB
Dong et al. The expression signatures of neuronal nitric oxide synthase (NOS1) in turbot (Scophthalmus maximus L.) mucosal surfaces against bacterial challenge
RU2016116708A (ru) Олигопептиды металлопротеиназ и их терапевтическое применение
CN1867252A (zh) 多糖与用于癌症治疗的化疗剂的共同给药
WO2017067510A1 (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用
CN110742880A (zh) Cl419在制备治疗炎性肠病药物中的用途
CN111420025B (zh) 茜草科类型环肽化合物在制备cGAS-STING信号通路激活剂的药物中的应用
WO2013004069A1 (zh) 沙门氏菌鞭毛蛋白衍生物在制备防治炎症性肠病药物中的应用
CN1860229A (zh) 一种具有抑癌作用的重组蛋白及其编码基因与应用
CN116459260A (zh) 一种特异性靶向nlrp3炎症小体抑制剂的用途
JP5635779B2 (ja) Stx毒性阻害ペプチドおよびStxに起因する疾患の治療薬
WO2017089555A1 (en) Il-34 antisense oligonucleotides and methods of using same
CN110638803A (zh) Dencichine在制备治疗炎性肠病药物中的用途
WO2012147805A1 (ja) 脳移行性機能性核酸及びその利用
EP2870135A1 (en) Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors
CN103405787A (zh) 一种基于miR-141的分子靶向核酸纳米药物及其制备方法和应用
US10849861B2 (en) Pharmaceutical compound for treating colorectal cancer
WO2021252718A1 (en) Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus
JP6841404B2 (ja) ペプチド

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200204

RJ01 Rejection of invention patent application after publication